Early treatment of multiple sclerosis: A Latin American Experts Meeting

2009 ◽  
Vol 15 (3_suppl) ◽  
pp. 1-12 ◽  
Author(s):  
O Garcea ◽  
A Villa1 ◽  
F Cáceres ◽  
T Adoni ◽  
M Alegría ◽  
...  
Keyword(s):  
Multiple Sclerosis ◽  
Effective Treatment ◽  
Latin American ◽  
Preventive Treatment ◽  
Clinically Isolated Syndrome ◽  
Clinical Settings ◽  
Immunomodulating Drug ◽  
Patient Prognosis ◽  
To Receive ◽  
Review Current

Patients with clinically isolated syndrome (CIS) by definition do not have multiple sclerosis (MS) but are at risk of developing it. While studies show earlier immunomodulating drug use is effective, treatment must consider likely patient prognosis. In this paper we review current diagnosis, prognosis, and treatment literature for patients with CIS within Latin American clinical settings. Latin American MS experts, convened by ACINDES (The Civil Association for Research and Development in Health), reviewed current CIS (and early MS) literature and drew consensus conclusions. Three subgroups addressed separate questionnaires on CIS issues: prognosis, diagnosis, and treatment. MRI can contribute to predicting MS risk in patients with CIS; in Latin America, investigation of haplotype presence associated with CIS would be appropriate. McDonald's criteria and subsequent revisions enable earlier, more accurate MS diagnosis. Type A evidence exists supporting all leading immunomodulating MS drugs for effective treatment of CIS with a high risk of conversion to MS. In conclusion, patients with CIS are usually young, with often-limited symptomatic manifestations, and must be adequately prepared to receive preventive treatment. This consensus review should contribute to the dialogue between physicians and patients. Multiple Sclerosis 2009; 15: S1–S12. http://msj.sagepub.com

No impact of adult attachment and temperament on clinical variability in patients with clinically isolated syndrome and early multiple sclerosis

2013 ◽  
Vol 115 (3) ◽  
pp. 293-297 ◽  
Author(s):  
Christian Fazekas ◽  
Michael Khalil ◽  
Christian Enzinger ◽  
Franziska Matzer ◽  
Siegrid Fuchs ◽  
...  
Keyword(s):  
Multiple Sclerosis ◽  
Adult Attachment ◽  
Clinically Isolated Syndrome ◽  
Clinical Variability

Autonomic dysfunction in clinically isolated syndrome suggestive of multiple sclerosis

2016 ◽  
Vol 127 (1) ◽  
pp. 864-869 ◽  
Author(s):  
Luka Crnošija ◽  
Ivan Adamec ◽  
Mila Lovrić ◽  
Anamari Junaković ◽  
Magdalena Krbot Skorić ◽  
...  
Keyword(s):  
Multiple Sclerosis ◽  
Autonomic Dysfunction ◽  
Clinically Isolated Syndrome

Extended dosing of monoclonal antibodies in multiple sclerosis

2021 ◽  
pp. 135245852110657
Author(s):  
Zoé LE van Kempen ◽  
Alyssa A Toorop ◽  
Finn Sellebjerg ◽  
Gavin Giovannoni ◽  
Joep Killestein
Keyword(s):  
Multiple Sclerosis ◽  
Monoclonal Antibodies ◽  
Treatment Options ◽  
Future Research ◽  
Therapeutic Drug ◽  
Therapeutic Landscape ◽  
Anti Cd20 ◽  
Dosing Intervals ◽  
Care Costs ◽  
Review Current

Over the past two decades, treatment options for patients with multiple sclerosis (MS) have increased exponentially. In the current therapeutic landscape, “no evidence of MS disease activity” is within reach in many of our patients. Minimizing risks of complications, improving treatment convenience, and decreasing health care costs are goals that are yet to be reached. One way to optimize MS therapy is to implement personalized or extended interval dosing. Monoclonal antibodies are suitable candidates for personalized dosing (by therapeutic drug monitoring) or extended interval dosing. An increasing number of studies are performed and underway reporting on altered dosing intervals of anti-α4β1-integrin treatment (natalizumab) and anti-CD20 treatment (ocrelizumab, rituximab, and ofatumumab) in MS. In this review, current available evidence regarding personalized and extended interval dosing of monoclonal antibodies in MS is discussed with recommendations for future research and clinical practice.

Quality of life in individuals newly diagnosed with multiple sclerosis or clinically isolated syndrome

2021 ◽  
Author(s):  
Kevin N. Alschuler ◽  
Daniel Whibley ◽  
Anna L. Kratz ◽  
Mark P. Jensen ◽  
Annette Wundes ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Multiple Sclerosis ◽  
Clinically Isolated Syndrome ◽  
Newly Diagnosed

Hearth and Home and Horror: Gothic Trappings in early C20th Latin American Short Fiction

2021 ◽  
Vol 23 (2) ◽  
pp. 201-216
Author(s):  
Megan DeVirgilis
Keyword(s):  
Latin America ◽  
Case Studies ◽  
Latin American ◽  
Short Fiction ◽  
Short Form ◽  
Gothic Novel ◽  
To Receive ◽  
American Authors ◽  
Scholarly Attention

The Gothic short form in Latin America has yet to receive focused scholarly attention. Yet, despite no early Gothic novel tradition to speak of, the Gothic mode emerged in poetry and short fiction, representing particular anxieties and colonial/postcolonial realities specific to the region owing in part to a significant increase in periodicals. Focusing on two case studies – Clemente Palma's ‘La granja blanca’ (Peru, 1904) and Horacio Quiroga's ‘El almohadón de plumas’ (Uruguay, 1917) – this article will explore how Latin American authors classified as modern, modernista, and criollista were experimenting with Gothic forms, adapting the design of the traditional Gothic novel to intensify its effect and reach a wider readership. Demonstrating a particular influence of Poe, a unity of effect is created, one that suggests that the home is a place of horrors, not comfort, and the uniquely horrifying settings and plot ultimately challenge established moral codes and literary tendencies.

Sign in / Sign up

Export Citation Format

Share Document